

#### **Challenges and Opportunities Facing NIH Peer-Review**

#### A Vision for Ensuring Its Strategic National Value



Center for Scientific Review National Institutes of Health Department of Health and Human Services

NCI National Cancer Advisory Board, February 6, 2007

#### Peer Review: An N.I.H. "Conception"

- Is the heart and soul of NIH
- Has created the best academic medical centers, the best biomedical/behavioral research and biotechnology
- Has made possible the best cures and the best prevention
- Has been admired and imitated in the U.S. and abroad
- Has protected NIH against outside influence



## **Center for Scientific Review**

## **CSR Peer Review**

- 80,000 applications received/ year
- 55,000 applications reviewed/ year
- 18,000 reviewers/ year
- 250 Scientific Review Administrators
- 1,800 review meetings a year

## NCI Applications Reviewed by CSR in FY 2003 and 2006

#### **Fiscal Year of Review**

	2003	2006
Number of applications reviewed by CSR (for all ICs)	41,716	51,798
Number of NCI applications reviewed by CSR Percent of total reviewed by CSR	<mark>6,277</mark> (15.0%)	7,715 (14.9%)
Number of CSR study section meetings	1,557	1,624
Number of CSR study sections meetings that reviewed NCI applications (Percent of total)	<b>577</b> (37.1%)	<mark>628</mark> (38.7%)

# NCI R01 Applications Reviewed by CSR in 2003 and 2006



#### What the Community is Saying



"The current NIH grant evaluation system . . . often resembles the evaluation process in American Idol." Michele Pagano, NYU School of Med.

#### **PRESIDENT'S Column**



#### Research Funding in the Time of Flat Budgets

The US Federal budget looks like it is in for a rough spell, especially for "discretionary" spending. After the recent doubling of

ing. After the recent doubling of the NIH budget, biomedical research funding is clearly a lower priority for Congress, the ability of which to increase funding for the NIH is severely limited in any case.

If funds allocated for research do not increase by at least the inflation rate for science, which is higher than general inflation, then a flat budget or even a small increase translates into a decrease in funds for new grants and The judging of grants has become a charade. To be funded, the experimental plan has become a litany of experiments already accomplished so that everything is feasible. When grants come back with unfundable scores, new investigators may not

> have sufficient resources to do the experiments that "show feasibility". What can we do to reverse this trend? New investigators should be encouraged to apply for extramural funding as early as possible, even when they have start-up funds. They should find

From progress to regression: biomedical research funding



H. Mandel, GWU E. Vesell, Penn State

"The judging of grants has become a charade." Zena Werb, President, ASCB

#### **Major Complaints About NIH Peer Review**

- The process is too slow
- There are not enough senior/experienced reviewers
- The process favors predictable research instead of significant, innovative, or transformative research
- Clinical research may not fare as well as other research
- The time and effort required to write, submit, resubmit, review and re-review is a heavy burden on applicants and reviewers

# The First NIH Study SectionThe Last NIH Study Section19462007







#### This Is Not Amazon.com











EnterpriseArchitecture@mail.nih.gov

Contact: enterprisearchitecture@mail.nih.gov



#### **A Vision for Peer Review**

- **1. Shorten the review cycle**
- 2. Improve study section alignment and performance
- 3. Address concern that clinical research is not properly evaluated
- Do more to recruit and retain more high-quality reviewers and decrease the burden on applicants and reviewers
- 5. Improve the identification of significant, innovative and high-impact research



**1. Shorten the review cycle** 



#### **Shortening the Review Cycle**

- Goal: To provide applicants for most mechanisms a review and score within 3 months so they could reapply with a revised application after one month (4 months earlier than in the past)
- 3 reviews within one year

#### **Shortening the NIH Review Cycle, Initial Steps**

#### **Summary Statements**

- Post all within 1 month of meeting (97.3%)
- Post new investigator summary statements within
   1 week

Pilot study with new investigators in 40 study sections who may revise and resubmit for the very next review cycle 4 months earlier than before (Started Feb 06)

#### Short Review Cycle Pilot of New Investigator R01 Applications

New Investigator R01 Applications	Applicatio Submitted July 2006	ns I for Round	*Applicati Submittee Nov. 2006	ions d for Round	Tota	l
Reviewed in Pilot	628	100 %	579	100%	1,207	100%
Amended/Submitted for the Next Round	83	13.2%	79	13.6%	162	13.4%

\* Not counting resubmissions from one Study Section (Due. Nov. 30.)

**Shortening the NIH Review Cycle, Next Steps** 

Extending the pilot for new R01 investigators:
Last year: 40 SS, about 2000 new investigators eligible per year
Feb 2007, 62 SS
June 2007, more than 100 SS
Nov 2007 All New Investigators



- 1. Shorten the review cycle
- 2. Improve study section alignment and performance



## **Biannual IRG Review Schedule**

#### Scheduled 2006 --14 IRGs

**Biological Chemistry and Macromolecular Biophysics (BCMB)** 

Cardiovascular Science (CVS)

**Bioengineering Sciences and Technologies (BST)** 

AIDS and Related Research (AARR)

**Risk, Prevention, and Health Behavior (RPHB)** 

Genes, Genomes and Genetics (GGG)

**Digestive Sciences (DIG)** 

Endocrinology, Metabolism, Nutrition and Reproductive Sciences (EMNR)

**Brain Disorders and Clinical Neuroscience (BDCN)** 

Integrative, Functional and Cognitive Neuroscience (IFCN)

Molecular, Cellular and Developmental Neuroscience (MDCN)

Hematology (HEME)

Immunology (IMM)

Health of the Population (HOP)

#### Scheduled 2007 -- 9 IRGs

Biology of Development and Aging (BDA)

Infectious Diseases and Microbiology (IDM)

**Biobehavioral and Behavioral Processes (BBBP)** 

Cell Biology (CB)

Musculoskeletal, Oral and Skin Sciences (MOSS)

**Oncological Sciences (ONC)** 

Surgical Sciences, Biomedical Imaging and Bioengineering (SBIB)

**Respiratory Sciences (RES)** 

**Renal and Urological Sciences (RUS)** 

#### **Six Open House Workshops**

Mar. 2, 2007	<b>Neurological (3):</b> Brain Disorders and Clinical Neuroscience (BDCN); Integrative, Functional and Cognitive Neuroscience (IFCN); Molecular, Cellular and Developmental Neuroscience (MDCN)
April 25, 2007	<b>Behavioral/Social (3):</b> Biobehavioral and Behavioral Processes (BBBP); Health of the Population (HOP); Risk Prevention and Health Behavior (RPHB)
Jun. 29, 2007	<b>Disease-based (4):</b> AIDS and Related Research (AARR); Infectious Diseases and Microbiology (IDM); Oncological Sciences (ONC); Surgical Sciences, Biomedical Imaging and Bioengineering (SBIB)
Aug.14, 2007	Integrated Biological (4): Digestive Sciences (DIG); Musculoskeletal, Oral and Skin Sciences (MOSS); Renal and Urological Sciences (RUS) Endocrinology, Metabolism, Nutrition and Reproductive Sciences (EMNR)
Oct. 30, 2007	Integrated Biological (5): Immunology (IMM); Hematology (HEME); Cardiovascular Sciences (CVS); Respiratory Sciences (RES); Biology of Development and Aging (BDA)
Dec. 18, 2007	<b>Biomolecular (4):</b> Biological Chemistry and Macromolecular Biophysics (BCMB); Bioengineering Sciences and Technologies (BST); Cell Biology (CB); Genes, Genomes and Genetics (GGG)

#### **A Vision for Peer Review**

- **1. Shorten the review cycle**
- 2. Improve study section alignment and performance
- 3. Address concern that clinical research is not properly evaluated



M. Martin, CSR/NIH/DHHS

### Significant Numbers of Clinical Grantees Are Not Submitting Renewal Applications

R01 Applications 2000-2004	HS+	HS-
Type 1 New A0	24.59%	20.20%
Type 2 A0	11.71%	17.11%

#### **A Vision for Peer Review**

- 1. Shorten the review cycle
- 2. Improve study section alignment and performance
- 3. Address concern that clinical research is not properly evaluated
- Do more to recruit and retain more high-quality reviewers and decrease the burden on applicants and reviewers

## **Changes Impacting CSR Peer Reviews**

	5 Years Ago	Now
Applications Received	46,000	80,000
R01s and R21s Reviewed by CSR	21,000	39,000
Applications/Applicant per Year	1.2	1.4
Average Number of Applications Reviewed by Reviewers	11.6	6

#### **CSR's Growing Need for Reviewers**





#### **The Advantages of Shorter Applications**

#### **Operational**

- Each reviewer can read more applications
- Study sections can be smaller
- More experienced reviewers can be recruited

#### Cultural

 Reviews can be more focused on impact and innovation and less on approach and preliminary results

## Goals

**Trans-NIH Committee to Shorten the Application** 

- Focus on the R01
- Consider reducing the page limit
- Align the application more closely with review criteria

Strong support by councils and scientific leadership, PRAC, IC Directors Retreat

#### **NIH Guide Survey on Shorter R01 Applications**

Reviewer Responses	Number	Percent
For Shorter Applications	3,174	74%
<b>Against Shorter Applications</b>	1,122	<b>26%</b>
Total	4,296	100%

**Total Responses: 5,078** 

# This is CSR





## National International Hope

